Beximco Pharmaceuticals Ltd. said Thursday that it has been granted a sub-license from the United Nations-backed Medicines Patent Pool to produce a generic version of Pfizer's Paxlovid oral treatment for Covid-19 Paxlovid.

The pharma company said it will manufacture the drug--which is an antiviral combination of nirmatrelvir and ritonavir--in Bangladesh following a successful technology transfer and regulatory approvals.

The Medicines Patent Pool aims to expand poor countries' access to drugs.

The drug received emergency use authorization in December 2021 FRP, the U.S. Food and Drug Administration for the treatment of mild-to-moderate Covid-19, Beximco said.

"This further collaboration with MPP is testament to our commitment to providing a broad selection of affordable treatments to combat Covid-19 in low- and middle-income countries, as well as our strong reputation as a producer of high-quality generic medicines," Managing Director Nazmul Hassan said.

Write to Michael Susin at michael.susin@wsj.com